MedTech Featured Stories
Bristol subpoenaed over foreign sales practices
U.S. drugmaker Bristol-Myers Squibb Co said on Thursday that it received a subpoena from securities regulators regarding its sales and marketing practices in various foreign countries.
Bristol-Myers, in a filing, said it received the subpoena from the U.S. Securities and Exchange Commission (SEC) last month in connection with an investigation under the Foreign Corrupt Practices Act (FCPA).
Return to Previous Page